ArticleFrontiers in neuroinformatics2025
Epileptic brain imaging by source localization CLARA supported by ictal-based semiology and VEEG in resource-limited settings.
Article in Frontiers in neuroinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Celiac Disease and the Nervous System: A Comprehensive Overview of Neurological Manifestations and Underlying Mechanisms.Neuromolecular medicine · 2026Review
- Epilepsy: Bridging Epidemiological Landscapes, Molecular Mechanisms, and Emerging Precision Therapeutics.Neuropsychiatric disease and treatment · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate localization of the epileptogenic zone is essential for surgical treatment of drug-resistant epilepsy. Standard presurgical evaluations rely on multimodal neuroimaging techniques, but these may be limited by availability and interpretive challenges. This study aimed to assess the concordance between zones identified by ictal semiology and a novel distributed electrical source localization technique, CLARA, and to evaluate their impact on postsurgical outcomes. Methods: This retrospective study included 16 patients with at least three recorded seizures. Ictal semiology was analyzed subjectively using video electroencephalography (VEEG) by a multidisciplinary team of neurologists, neurophysiologists, and radiologists, who determined the presumed epileptogenic zone at the lobar level. CLARA was subsequently applied to identify the computed zone based on ictal and/or interictal biomarker activities. The concordance between the presumed and computed zones was assessed qualitatively. Postsurgical outcomes were examined in relation to the extent of resection of the CLARA-defined zones. Results: Among thirteen patients with sufficient data for analysis, qualitative comparison showed 77% concordance and 23% partial concordance between the presumed and computed zones. Postsurgical follow-up revealed seizure freedom in one patient with cavernoma following complete resection of the CLARA-defined zone. In contrast, patients with incomplete resection of this region continued to experience seizures. Discussion: The findings support the potential value of CLARA as an adjunctive neuroimaging technique in the presurgical evaluation of epilepsy. By providing an additional layer of verification, CLARA may improve the accuracy of epileptogenic zone localization when used alongside established modalities such as PET, SPECT, fMRI, and MRI. Its adaptability and lower resource requirements suggest particular utility in centers with limited access to advanced medical equipment and specialized personnel. Broader implementation of CLARA could enhance presurgical decision-making and contribute to improved surgical outcomes for epilepsy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.